New domestic anti-cancer drugs embark on a virtuous circle, and many pharmaceutical companies recently announced new breakthroughs

In recent years, in the Chinese drug market, the sales of anti-tumor drugs have been showing steady growth.
Data shows that in 2020, the size of this drug market will reach 197.
5 billion yuan, and it is estimated that the market size will reach 284.
5 billion yuan in 2022
.

The compound annual growth rate of China's anti-tumor drug market from 2020 to 2025 is about 16%

There is huge market demand for anti-tumor drugs, and major pharmaceutical companies have deployed one after another.
In recent years, with the continuous improvement of domestic pharmaceutical companies' innovation capabilities, domestic anti-tumor drugs have also continuously achieved new breakthroughs
.

For example, Zhejiang Medicine issued an announcement recently that the company's subsidiary Xinma Biology's new anti-cancer drug, a recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate for injection (code: ARX305), has been accepted for registration of clinical trials
.

It is understood that there is currently no marketed drug targeting CD70 at home and abroad
.

According to literature estimates, the annual increase in the number of patients with CD70-positive representative tumors in China exceeds 100,000.

According to the data, ARX305 is a new generation of monoclonal antibody conjugate drug jointly developed by Zhejiang Pharmaceuticals after signing the "Cooperative Development and License Agreement" with Ambrx in the United States on October 22, 2019.
It is used to treat advanced tumors expressing CD70.
Innovative biotechnology drugs
.

As of November 30, 2021, Zhejiang Medicine has invested a total of 65.

Increasing the innovative research and development of domestic anti-tumor drugs to provide more cancer patients with new drug treatment options.
Domestic pharmaceutical companies are making continuous efforts
.

On the evening of December 17, Haite Bio also released a piece of good news
.

The announcement stated that the company's application for the marketing authorization of the recombinant allosteric human tumor necrosis factor-related apoptosis-inducing ligand (Circularly Permuted TRAIL, referred to as "CPT") for injection has been accepted by the State Food and Drug Administration

Data show that this is a new targeted anti-tumor drug suitable for multiple myeloma.
Currently, no drugs with the same target are on the market at home or abroad
.

It is foreseeable that once the drug is on the market, it will open up a new treatment field for the treatment of multiple myeloma and bring good news to patients

In addition, Hengrui Medicine recently registered a phase I clinical trial (CTR20213220) of the subcutaneous injection PD-1 product SHR-1901 on the drug clinical trial registration and information disclosure platform
.

It is worth noting that this is the first clinical trial of PD-1 subcutaneous injection in China, and it is also the second PD-1 antibody developed by Hengrui Medicine

According to industry insiders, the toxic and side effects of PD-1 drugs in subcutaneous injection formulations are significantly better than those in intravenous formulations.
In particular, tumor treatment is a long-term process.
Subcutaneous injection patients can be completed at home, which can greatly improve the convenience of medication.
It is an important research and development direction
.

It is understood that in the past ten years, with the strong support of national favorable policies, the continuous investment and the introduction of talents from China's national pharmaceutical companies, focusing on clinical needs, and the courage to pioneer and innovate, the research and development of innovative anti-tumor drugs in China has shown a very good development.
Trend
.

New drug R&D has gradually transitioned from the me too stage to the real innovative drug R&D stage.
What is even more anticipated is that some first-in-class new drugs have also emerged, and the domestic new drug R&D strength has gradually been recognized by the overseas market
.

According to the industry, at present, the research and development of new anti-tumor drugs in China is transitioning from the imitation stage to the independent innovation stage, and will embark on a virtuous circle